iDetect KC Videos: Diagnosing Keratoconus and Keratoconus Management

Mitch Ibach, OD, FAAO

Vance Thompson Vision, Sioux Falls, SD

Dr. Mitch Ibach discusses the iDetect KC Program in the context of keratoconus management through early diagnosis of patients and early intervention with treatment.

Learn About iDetect KC

Melissa Barnett, OD, FAAO, FSLS, FBCLA

Davis Eye Center, Sacramento, CA

Dr. Melissa Barnett presents the iDetect KC Program at the Global Specialty Lens Symposium to help optometrists diagnose keratoconus earlier and manage the condition.

Learn About iDetect KC

Please Select Your Country

Continue

Using Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution), Photrexa® (riboflavin 5’-phosphate ophthalmic solution), and the KXL® System, the iLink® corneal cross-linking procedure from Glaukos is the only FDA-approved therapeutic treatment for patients with progressive keratoconus and corneal ectasia following refractive surgery.*1

[Photrexa IFU/p1/col1/para3/lines1-4]

Important Safety Information

Corneal collagen cross-linking should not be performed on pregnant women.

Ulcerative keratitis can occur. Patients should be monitored for resolution of epithelial defects. The most common ocular adverse reaction was corneal opacity (haze). Other ocular side effects include punctate keratitis, corneal striae, dry eye, corneal epithelium defect, eye pain, light sensitivity, reduced visual acuity, and blurred vision.

These are not all the side effects of the corneal collagen cross-linking treatment. For more information, go to Prescribing Info to obtain the FDA-approved product labeling.

You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

*Photrexa® Viscous and Photrexa® are manufactured for Avedro. The KXL® System is manufactured by Avedro. Avedro is a wholly owned subsidiary of Glaukos Corporation.

Indications

Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5’-phosphate ophthalmic solution) are indicated for use with the KXL System in corneal collagen cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery.

Reference

1. Photrexa Prescribing Information. Burlington, MA: Avedro, a Glaukos company 2022